Abstract
Uveal melanoma is a rare and biologically distinct type of melanoma arising from melanocytes of the uveal tract; it is associated with a poor prognosis due to the lack of effective systemic treatments. Recent advances in the pathogenesis of uveal melanoma offer an unprecedented opportunity for investigation of new compounds. The purpose of this paper was to analyse the existing evidence about the molecular pathology and immunobiology of advanced uveal melanoma and their implications for systemic targeted therapies and immunotherapy, as well as to discuss future treatment strategies based on data provided by clinical and translational research studies.
| Original language | English |
|---|---|
| Pages (from-to) | 1-12 |
| Number of pages | 12 |
| Journal | BioDrugs |
| DOIs | |
| Publication status | Accepted/In press - Mar 21 2016 |
Fingerprint
ASJC Scopus subject areas
- Pharmacology (medical)
- Pharmacology
- Biotechnology
Cite this
Update on Metastatic Uveal Melanoma : Progress and Challenges. / Spagnolo, Francesco; Picasso, Virginia; Spano, Laura; Tanda, Enrica; Venzano, Clary; Queirolo, Paola.
In: BioDrugs, 21.03.2016, p. 1-12.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Update on Metastatic Uveal Melanoma
T2 - Progress and Challenges
AU - Spagnolo, Francesco
AU - Picasso, Virginia
AU - Spano, Laura
AU - Tanda, Enrica
AU - Venzano, Clary
AU - Queirolo, Paola
PY - 2016/3/21
Y1 - 2016/3/21
N2 - Uveal melanoma is a rare and biologically distinct type of melanoma arising from melanocytes of the uveal tract; it is associated with a poor prognosis due to the lack of effective systemic treatments. Recent advances in the pathogenesis of uveal melanoma offer an unprecedented opportunity for investigation of new compounds. The purpose of this paper was to analyse the existing evidence about the molecular pathology and immunobiology of advanced uveal melanoma and their implications for systemic targeted therapies and immunotherapy, as well as to discuss future treatment strategies based on data provided by clinical and translational research studies.
AB - Uveal melanoma is a rare and biologically distinct type of melanoma arising from melanocytes of the uveal tract; it is associated with a poor prognosis due to the lack of effective systemic treatments. Recent advances in the pathogenesis of uveal melanoma offer an unprecedented opportunity for investigation of new compounds. The purpose of this paper was to analyse the existing evidence about the molecular pathology and immunobiology of advanced uveal melanoma and their implications for systemic targeted therapies and immunotherapy, as well as to discuss future treatment strategies based on data provided by clinical and translational research studies.
UR - http://www.scopus.com/inward/record.url?scp=84961793487&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84961793487&partnerID=8YFLogxK
U2 - 10.1007/s40259-016-0167-4
DO - 10.1007/s40259-016-0167-4
M3 - Article
SP - 1
EP - 12
JO - Clinical Immunotherapeutics
JF - Clinical Immunotherapeutics
SN - 1173-8804
ER -